Geron reported $519.01M in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Amgen USD 95.64B 3.14B Jun/2026
Bio Techne USD 2.59B 36.12M Jun/2026
Cassava Sciences USD 108.37M 9.99M Mar/2026
Cytokinetics USD 1.92B 651.07M Jun/2026
Exelixis USD 2.49B 99.36M Jun/2026
Genmab DKK 12.52B 139M Jun/2026
Geron USD 519.01M 15.11M Jun/2026
Gilead Sciences USD 49.36B 6.92B Jun/2026
Incyte USD 7.87B 533.53M Jun/2026
MacroGenics USD 345.41M 127.54M Jun/2026
Novartis USD 122.03B 3.5B Jun/2026
Novavax USD 955.58M 87.59M Jun/2026